Testing the “Ramdevpir” will continue for another two months to prove the effectiveness of the drug. On Monday, July 6, said the chief researcher of the world health organization (who) Sumia Swaminathan.
“The second phase will begin after about a couple of months. The completion of the first phase will require some time. The country can always publish extra recommendations. But still (from “Ramdevpir”, — ed.) there is no benefit in reducing mortality. The official who recommendations about the drug yet,” said Swaminathan in conversation with “RIA Novosti”.
She noted that tests on the effectiveness of the drug will last a few months before the completion of the first phase of testing. As for the second phase, that under it who would create the Committee, which will determine the list of drugs involved in new trials.
In particular, discusses the various immunomodulators, antiplatelet drugs and mononuclear antibodies.
However, a few days ago, Swaminathan said that “Ramdevpir” is the only tested drug that has shown encouraging result.
In mid-may, President of the International society of research in the field of antiviral drugs, chemist Katherine Floods-Radtke noted that the effectiveness of “Ramdevpir” you can only talk when it is used in combination with other medications.